Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takako Inoue

Showing results (111-120 of 144) with videos related to

Pageof 15
Sort By:
Clinical Lung Cancer|November 15, 2017
Analysis of Early Death in Japanese Patients With Advanced Non-small-cell Lung Cancer Treated With NivolumabTakako Inoue, Motohiro Tamiya, Akihiro Tamiya, et al.
Plos One|February 23, 2018
Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trialMotohiro Tamiya, Akihiro Tamiya, Takako Inoue, et al.
Cancer Treatment and Research Communications|August 4, 2024
Impact of body surface area on efficacy and safety in patients with EGFR-mutant non-small cell lung cancer treated with osimertinib as a first-line treatmentSaki Tanaka, Motohiro Tamiya, Satoshi Nishiuma, et al.
Oxford Medical Case Reports|June 30, 2022
Successful weaning of a patient with severe COVID-19 pneumonia under prolonged midazolam sedation using morphineKei Kunimasa, Yoshifumi Ohashi, Megumi Okawa, et al.
Annals of Hepatology|December 5, 2024
Clinical usefulness of an ultra-high-sensitivity hepatitis B surface antigen assay to determine the cessation of treatment for HBV reactivationTakanori Suzuki, Akihiro Tamori, Kentaro Matsuura, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|February 28, 2023
Efficacy and safety of mycophenolate mofetil in treating immune-related hepatitis induced by immune checkpoint inhibitor use: A retrospective studyYukio Kadokawa, Satoko Inoue, Akitoshi Tatsumi, et al.
Future Oncology (London, England)|June 4, 2020
Improvement strategies for successful next-generation sequencing analysis of lung cancerKei Kunimasa, Shingo Matsumoto, Kazumi Nishino, et al.
Anticancer Research|July 31, 2020
A Multivariable Regression Model-based Nomogram for Estimating the Overall Survival of Patients Previously Treated With Nivolumab for Advanced Non-small-cell Lung CancerAkihiro Tamiya, Motohiro Tamiya, Hirofumi Go, et al.
Lung Cancer (Amsterdam, Netherlands)|October 1, 2018
Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutationsKen Uchibori, Miyako Satouchi, Naoko Sueoka-Aragane, et al.
Cancer Genetics|June 15, 2021
EML4-ALK fusion variant.3 and co-occurrent PIK3CA E542K mutation exhibiting primary resistance to three generations of ALK inhibitorsKei Kunimasa, Yosuke Hirotsu, Yoji Kukita, et al.
Pageof 15

Showing results (111-120 of 144) with videos related to

Sort By:
Pageof 15
Clinical Lung Cancer|November 15, 2017
Analysis of Early Death in Japanese Patients With Advanced Non-small-cell Lung Cancer Treated With NivolumabTakako Inoue, Motohiro Tamiya, Akihiro Tamiya, et al.
Plos One|February 23, 2018
Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trialMotohiro Tamiya, Akihiro Tamiya, Takako Inoue, et al.
Cancer Treatment and Research Communications|August 4, 2024
Impact of body surface area on efficacy and safety in patients with EGFR-mutant non-small cell lung cancer treated with osimertinib as a first-line treatmentSaki Tanaka, Motohiro Tamiya, Satoshi Nishiuma, et al.
Oxford Medical Case Reports|June 30, 2022
Successful weaning of a patient with severe COVID-19 pneumonia under prolonged midazolam sedation using morphineKei Kunimasa, Yoshifumi Ohashi, Megumi Okawa, et al.
Annals of Hepatology|December 5, 2024
Clinical usefulness of an ultra-high-sensitivity hepatitis B surface antigen assay to determine the cessation of treatment for HBV reactivationTakanori Suzuki, Akihiro Tamori, Kentaro Matsuura, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|February 28, 2023
Efficacy and safety of mycophenolate mofetil in treating immune-related hepatitis induced by immune checkpoint inhibitor use: A retrospective studyYukio Kadokawa, Satoko Inoue, Akitoshi Tatsumi, et al.
Future Oncology (London, England)|June 4, 2020
Improvement strategies for successful next-generation sequencing analysis of lung cancerKei Kunimasa, Shingo Matsumoto, Kazumi Nishino, et al.
Anticancer Research|July 31, 2020
A Multivariable Regression Model-based Nomogram for Estimating the Overall Survival of Patients Previously Treated With Nivolumab for Advanced Non-small-cell Lung CancerAkihiro Tamiya, Motohiro Tamiya, Hirofumi Go, et al.
Lung Cancer (Amsterdam, Netherlands)|October 1, 2018
Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutationsKen Uchibori, Miyako Satouchi, Naoko Sueoka-Aragane, et al.
Cancer Genetics|June 15, 2021
EML4-ALK fusion variant.3 and co-occurrent PIK3CA E542K mutation exhibiting primary resistance to three generations of ALK inhibitorsKei Kunimasa, Yosuke Hirotsu, Yoji Kukita, et al.
Pageof 15